JPRN-UMIN000016013已完成未知
Clinical study of tube administration speed of viscosity modifiered enteral fomula - tube administration speed of viscosity modifiered enteral fomula
VF researching group0 个研究点目标入组 15 人开始时间: 2015年1月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The patients who are cirtified as contraindication case of this study by attending doctor. The patients out of indication for tube feeding. The patients have a complication durig the study.
研究者
相似试验
招募中
Unknown
Clinical implementation of the infusion rate individualization of intravenous lipid emulsioJPRN-UMIN000054236Kobe Gakuin University120
已完成
Unknown
To see the speed of anaesthesia with the drug thiopentone and compare it in patients with different heart lesionsCTRI/2023/03/051102ALL INDIA INSTITUTE OF MEDICAL SCIENCES NEW DELHI154
招募中
不适用
A Clinical Trial for Accuracy of the new IV flow Regulator applied by the IV Flow Rate Calibrating DeviceDiseases of the circulatory systemKCT0002637Eulji University250
进行中（未招募）
不适用
Pharmacokinetical-clinical study of intravescical gemcitabine in patients with marker lesion of superficial transitional cell carcinoma of the bladder - NDPatients with superficial transitional cell carcinoma of the bladderMedDRA version: 6.1Level: PTClassification code 10005003EUCTR2007-001942-42-ITAZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
进行中（未招募）
不适用
A Phase I-IIa Study of Dose escalating Intravesical AdCD40L instillation in Urinary Bladder Carcinomarinary bladder cancer is an attractive target for immunostimulating gene therapy because it is sensitive for immunotherapy as demonstrated by the life-prolonging effect of bacillus Calmette-Guérin (BCG) instillations. Phase I: Patients with infiltrative cancer of the urinary bladder and scheduled for cystectomy.Phase IIa: Patients with non-infiltrative cancer of the urinary bladder, stages Ta and scheduled for resectionEUCTR2006-000985-34-SEClinical Immunology Division30